Diagnosis and treatment of TB, HIV-associated TB and drug-resistant TB
Diagnosis of TB in 2015
In 2015, 6.4 million people with TB were notified to national TB programmes and reported to WHO. Of these, just over 6.1 million had an incident episode (new or relapse) of TB. The number of new and relapse TB cases notified and the notification rate per 100 000 population increased globally in 2013–2015, mostly explained by a 34% increase in notifications in India.
30% of the 3.4 million new bacteriologically confirmed and previously treated TB cases notified globally were reported to have had drug susceptibility testing for rifampicin. 132 000 cases of multidrug-resistant TB or rifampicin-resistant TB (MDR/RR-TB) were detected and notified and 125 000 were enrolled on treatment (20% of the estimated 580 000 people newly eligible for MDR-TB treatment).
55% of notified TB patients had a documented HIV test result, an 18-fold increase in testing coverage since 2004.
The proportion of HIV-positive TB patients on antiretroviral therapy was 78%.
Treatment outcomes of patients notified in 2014 (excluding patients moved to second-line treatment)
83% of new and relapse TB patients were successfully treated.
69% of previously treated (excluding relapse) TB patients were successfully treated.
75% of HIV-positive TB patients were successfully treated.
Treatment outcomes of patients started on MDR-TB or XDR-TB treatment in 2014
52% of MDR-TB patients were successfully treated.
28% of XDR-TB patients were successfully treated.